Donneau, Anne-Françoise ; Université de Liège - ULiège > Département des sciences de la santé publique > Informatique médicale et biostatistique
Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Language :
English
Title :
Cardiovascular safety of strontium ranelate: real-life assessment in clinical practice.
European Medicines Agency (2012) Good pharmacovigilance practices. Available at: www.ema.europa.eu. Accessed 4 November 2013
European Medicines Agency (2013) PSUR assessment report for strontium ranelate. Available at: www.ema.europa.eu. Accessed 4 November 2013
Cooper C, Fox KM, Borer JS (2013) Ischaemic cardiac events and use of strontium ranelate in postmenopausal osteoporosis: a nested case-control study in the CPRD. Osteoporos Int. doi:10.1007/s00198-013-2582-4
Abrahamsen B, Grove EL, Vestergaard P (2013) Nationwide registry-based analysis of cardiovascular risk factors and adverse outcomes in patients treated with stronium ranelate. Osteoporos Int. doi:10.1007/s00198-013-2469-4
Cooper C, Reginster JY, Cortet B et al (2012) Long-term treatment of osteoporosis in postmenopausal women: a review from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF). Curr Med Res Opin 28:475-491
Rizzoli R, Reginster JY, Boonen S et al (2011) Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis. Calcif Tissue Int 89:91-104
Rizzoli R, Reginster JY (2011) Adverse drug reactions to osteoporosis treatments. Expert Rev Clin Pharmacol 4:593-604
Kanis JA, McCloskey EV, Johansson H et al (2013) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 24:23-57
